1061 results about "Tumor targeting" patented technology

Peptide ligands having affinity for serum albumin are useful for tumor targeting. Conjugate molecules comprising a serum albumin binding peptide fused to a biologically active molecule demonstrate modified pharmacokinetic properties as compared with the biologically active molecule alone, including tissue (e.g., tumor) uptake, infiltration, and diffusion.

A composition for delivering a tumor therapeutic agent to a patient includes a fast-release formulation of a tumor apoptosis inducing agent, a slow-release formulation of a tumor therapeutic agent, and a pharmaceutically acceptable carrier. An apoptosis-inducing agent in a pharmaceutically acceptable carrier may be administered before or concomitantly therewith. Nanoparticles or microparticles (e.g., cross-linked gelatin) of the therapeutic agent (e.g., paclitaxel) also may be used. The nanoparticles or microparticles may be coated with a bioadhesive coating. Microspheres that agglomerate to block the entrance of the lymphatic ducts of the bladder to retard clearance of the microparticles through the lymphatic system also may be employed. This invention also uses drug-loaded gelatin and poly(lactide-co-glycolide) (PLGA) nanoparticles and microparticles to target drug delivery to tumors in the peritoneal cavity, bladder tissues, and kidneys.

The present application discloses the preparation and use of attenuated tumor-targeted bacteria vectors for the delivery of one or more primary effector molecule(s) to the site of a solid tumor. The primary effector molecule(s) of the invention is used in the methods of the invention to treat a solid tumor cancer such as a carcinoma, melanoma, lymphoma, or sarcoma. The invention relates to the surprising discovery that effector molecules, which may be toxic when administered systemically to a host, can be delivered locally to tumors by attenuated tumor-targeted bacteria with reduced toxicity to the host. The application also discloses to the delivery of one or more optional effector molecule(s) (termed secondary effector molecules) which may be delivered by the attenuated tumor-targeted bacteria in conjunction with the primary effector molecule(s).

Peptide ligands having affinity for serum albumin are useful for tumor targeting. Conjugate molecules comprising a serum albumin binding peptide fused to a biologically active molecule demonstrate modified pharmacokinetic properties as compared with the biologically active molecule alone, including tissue (e.g., tumor) uptake, infiltration, and diffusion.

The invention provides a folic acid and polydopamine modified tumor targeted mesoporous silica nanoparticle and a preparation method and application thereof. The preparation method particularly comprises the following steps: (1) dissolving mesoporous silica and a chemical in a solvent, performing a full reaction, and performing separation; (2) adding mesoporous silica initial nano-particles obtained in the step (1) in a solution, adding dopamine hydrochloride, performing a full reaction, and performing separation; and (3) adding the dopamine hydrochloride coated mesoporous silica initial nano-particles loaded with the chemical in a weakly basic water solution, sequentially adding a reducing agent and polyethylene glycol modified sulfydryl grafted targeted ligand folic acid, performing a full reaction, then performing separation to obtain the folic acid and polydopamine modified tumor targeted mesoporous silica nanoparticle. The preparation method of the folic acid and polydopamine modified tumor targeted mesoporous silica nanoparticle is simple, and favorable tumor targeting ability, biocompatibility and biodegradability are achieved.

The invention relates to a common carrier material based on graphene oxide for a targeting anticancer drug and a gene and application and application. Folic acid, lactobionic acid and other tumor cell targeting or liver targeting molecules and part of amino groups of soluble chitosan are connected by amide bonds to prepare a conjugate, the conjugate is then connected with graphene oxide, quaternization is performed by using an epoxy compound with a quaternary ammonium group, and gene molecules are loaded by the quaternizationquaternized part of the chitosan through electrostatic attraction; and then the anticancer drug is loaded by pi-pi conjugates, hydrogen bonds and hydrophobic effects in a non-covalent bond method. By adopting the targeting performance of targeting molecules and effects of graphene oxide of a particular size to enhance penetration and retention in tumor tissues and combining the performance of the graphene oxide for pH response control release of the loaded drug, the drug can be realized released in a tumor cell, an intelligent delivery system for the common carrier of the tumor targeting or liver targeting anticancer drug and the gene is synthesized from the perspective of synergetic medication, and a theoretical basis and a method basis are provided for combined therapy of tumor.

The present invention relates to polymer-modified quinone-containing and carbonyl-containing therapeutic agents, including polymer-modified β-lapachone compounds, and methods of treating cancer by administering the polymer-modified therapeutic agents to a subject. Polymer-modification of therapeutic agents, such as β-lapachone compounds, provides effective transport of polymer-modified therapeutic agents to tumor cells or tumor tissues by exploiting the EPR effect in tumor tissues.

The invention relates to a heptamethine indocyanine dye containing N-fatty esters or N-fatty amide side chains, a synthetic method thereof and applications thereof in tumor targeting imaging and treatment. The heptamethine indocyanine dye which possesses or individually possesses near infrared absorption, fluorography and antineoplastic activity allows present research and development ideas and treatment levels of tumor targeting treatment medicaments to be greatly improved, and has great significances to aspects of early discovery, control and the like of various tumors.

The invention relates to a pH and oxidation-reduction dual-sensitive layer cross-linking nanoparticle as well as a preparation method and an application thereof. A hydrophilic layer which at least contains PCB (Polycarboxylate Betaine) or PEG (Polyethylene Glycol) is positioned on the surface of the nanoparticle, a hydrophobic nuclei which at least contains a pH-sensitive polymer unit is positioned in the nanoparticle, and an S-S (Disulfide Bond) cross-linking layer which is formed through cross-linking reaction between PDS (Polymethacrylamide Ehtylpyridine Disulfide) units is positioned between the hydrophilic layer and the hydrophobic nuclei. A tumor targeted group can be modified on the hydrophilic layer positioned on the surface of the pH and oxidation-reduction dual-sensitive layer cross-linking nanoparticle, and the gathering of the nanoparticle on a tumor tissue and the endocytosis of the nanoparticle on the tumor cell are accelerated through the specific targeted effect of the nanoparticle on a tumor cell. The pH and oxidation-reduction dual-sensitive layer cross-linking nanoparticle disclosed by the invention has the advantages of good biocompatibility and low toxicity. According to the pH and oxidation-reduction dual-sensitive layer cross-linking nanoparticle, a cross-linked structure is dissociated under the action of glutathione inside the tumor cell, so that the release of a medicine is promoted. The preparation method disclosed by the invention is simple, convenient, good in stability and conveniently operated and popularized.

The invention provides a BCMA-based (B cell maturation antigen-based) chimeric antigen receptor, comprising following cis-form cascade domains: CD8a leader region, scFv fragment BCMA scFv of anti-BCMA antibody, CD8a hinge region and transmembrane region, CD28 intracellular signal domain and CD3 Zeta intracellular signal domain; the CD3 Zeta intracellular signal domain is wild CD3 Zetaintracellular signal domain or mutant CD3 Zeta mut intracellular signal domain; the BCMA-based chimeric antigen receptor can enhance anti-apoptotic capability of T-cells and enhance CAR T-cell and antigen bonding and signal conduction; T-cells with the BCMA-based chimeric antigen receptor show good tumor targeting performance in in-vivo experiments, tumors diminish significantly after two weeks of dosage, and the T-cells have excellent therapeutic effect in vivo.

The invention relates to a multifunctional magnetic nano particle and a preparation method thereof. The multifunctional magnetic nano particle has a core-shell structure, wherein the core is a medical magnetic nano particle, and the shell is photodynamic drug loaded nano silica with a mesoporous structure, hydrophilic groups and a targeting reagent which are safe to human bodies or animals are also modified on the shell. The specific surface area (BET) of the multifunctional magnetic nano particle is 600m<2>/g-800m<2>/g. The multifunctional magnetic nano particle has good controllable functions, and integrates functions of tumor targeting, imaging and photodynamic therapy.

The invention provides a novel polypeptide modified tumor targeted liposome of a targeted integrin receptor. The novel polypeptide is mainly formed by covalent linkage of ring-shaped RGD and cell penetrating peptides, and not only has the selective targeting capability of an integrin receptor, but also can achieve mediated endocytosis; the liposome mainly comprises phospholipid, cholesterol, lipid-polyethyleneglycol and lipid-polyethyleneglycol-novel polypeptide ligand chimeric substance, and is a very potential tumor targeted treatment carrier.

The invention discloses a method for preparing intelligent target medicine carrying composite micelles. The surfaces of the composite micelles are modified by target ligands and pH/temperature synergy sensitive polymers at the same time; and reversible transformation between the shielding state of the target ligands during blood circulation (the temperature is 37 DEG C, and the pH value is 7.4) and the deshielding state of the target ligands in tumor tissues (the thermal therapy temperature ranges from 40 DEG C to 44 DEG C, and the pH value ranges from 6.5 to 6.8) is achieved. The pH and temperature dual sensitivities used in the method have the synergy; and the method is more suitable for the complex physiological environment of the human body. The method has the beneficial effects that targeting of the target ligands and the sensitive phase transformation characters of the pH/temperature synergy sensitive polymers are sufficiently used; and a target reversible shielding nanometer drug delivery system with the tumor targeted specificity and the blood circulation stability is built.

The invention discloses a preparation method of PAMAM and CRISPR/Cas9 system recombinant plasmid delivering nanoparticles with tumor targeting. Firstly, Apt carboxyl is activated, Apt is reacted withamino on the surface of PAMAM to synthesize an Apt-PAMAM carrier, sgRNA is designed, an EGFR-sgRNA/Cas9 recombiant plasmid is constructed, and the recombiant plasmid and the carrier form an Apt-PAMAM/EGFR-sgRNA/Cas9 nano compound through electrostatic interaction. According to the compound, by means of compound surface-modified Apt active targeting tumor cell surface high expression EpCAM protein,tumor tissue targeting is improved; through a CRISPR/Cas9 gene editing technology, the recombiant plasmid of an EGFR-sgRNA gene is designed to knock out a high-expression EGFR gene in a tumor cell, so that the anti-tumor effect is achieved.

The invention discloses an exosome-encapsulated nano drug-loading system for tumor treatment, and preparation thereof. The system is obtained by utilizing cell endocytosis of a drug-loading nanometermaterial and then exocytosis. The drug-loading nanometer material is loaded with an antitumor medicine including at least one of a chemotherapeutic, a medicine used for immunotherapy and a medicine used for modifying a tumor microenvironment. The composition, structure and the like of the key outer component biofilm encapsulating the nano drug-loading system are improved, and compared with the prior art, the exosome-encapsulated nano drug-loading system provides a novel route for biofilm-based biological processed nanoparticles. By utilization of the exosome-encapsulated nano drug-loading system, the composition and the structure of the exosome can be maintained greatly, and the obtained exosome-encapsulated nano drug-loading system has good stability and tumor targeting performance duringblood circulation. .

The invention provides a hollow silicon magnetic microsphere, as well as the preparation method and the application thereof. The hollow silicon magnetic microspheres have the preparation method that a polystyrene/silicon dioxide composite microsphere is used as a core; Fe3O4 coats the periphery of the core through the layer-by-layer self-assembly method; then, a PS/SiO2/Fe3o4 polymeric magnetic composite nanosphere is obtained, and polystyrene is removed through the high temperature sintering method, thereby forming a magnetic material with hollow structure; the inner layer of the hollow magnetic material is SiO2, and the stability is good, thereby the material is not easy to collapse at high temperature; furthermore, the specific surface area of the material can be improved, and the material is a monodisperse hollow magnetic microsphere material. The method has the advantages of low cost and good repetitiveness. The obtained product not only can be used as a magnetic targeting drug carrier material, but also can be used in the biological and the medical fields such as biosensors, immunologic diagnosis, drug delivery and tumor targeting therapy as well as DNA isolation, etc.

The invention belongs to the technical field of biotechnology, and relates to a tumor-targeted diagnosis nuclear magnetic resonance contrast agent and a preparation method thereof. The tumor-target diagnosis nuclear magnetic resonance contrast agent is prepared from a high molecular material, polyethylene glycol, a polypeptide, a dual-function ligand and gadolinium chloride by taking the polypeptide as a target head group, taking the tree-like high polymer material as a basic high molecular vector and connecting a small molecular contrast agent to the surface. In the invention, a polypeptide-modified high molecular material screened by using a phage display technology enters cells in an endocytic way, so that the introjection of the contrast agent by tumor cells is increased, and the characteristic of high safety is achieved. The target head group polypeptide used in the invention has the advantages of transferrin, can be used for effectively avoiding the interference of endogenous transferrin, has high targeting and diagnosing efficiencies, is simple to prepare, and can be further applied to target diagnosis of other tumor tissues.